Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > For Us Neophytes Shareswappwe In Simple Terms

<< Previous

Bullboard Posts

Next >>

Comment by shareswapperon Dec 10, 2020 12:05am

67 Views

Post# 32074453

RE:For Us Neophytes Shareswappwe In Simple Terms

We've never conducted a Trial in Leishamaniasis so to be considered a key player we must have submitted an ANDA or Trial protocol to some group??? How and why did we get listed here? This is VERY excciting. This is a multi Billion (with a B) Dollar Market!!!

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property